Fair Value Calculator Fair Value Calculator
EN DE

RCAN (RCAN) Fair Value & Analysis

IN · Market cap ₹193M

R RCAN RCAN · BSE
Price₹18.36
Fair Value₹39.77
Upside+116.6%
Quality49/100
Watch RCAN for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹21.79 – ₹53.41

Fair value as of: Jul 5, 2026

From 26 valuation models · updated today

Share price −0.5% over the past month.

Price vs Fair Value (12 months)

₹202.75 ₹15.56 Fair Value ₹39.77 Jul 2025 Jul 2026

12‑month range ₹15.56 – ₹202.75 · fair‑value band ₹21.79 – ₹53.41 · the ₹18.36 price screens below the ₹39.77 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

RCAN (RCAN) currently trades at ₹18.36, while our model-based Fair Value estimate is ₹39.77 — implying the stock looks roughly 116.6% undervalued today. We read business quality at 49/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, RCAN generated revenue of ₹426M at a net margin of 5.3%. Revenue declined 1.8% year over year. It earns a return on equity of 17.1%. Net debt stands at ₹72.7M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹21.79 (bear case) to ₹53.41 (bull case); at ₹18.36, the current price sits below that range.

Key figures & financial health

Revenue (TTM) ₹426M
Revenue growth (YoY) -1.8%
Net margin 5.3%
Return on equity 17.1%
Free cash flow ₹22.7M FY2026
P/E ratio 8.6
More key figures
Operating margin 9.1%
EPS (TTM) ₹2.14
EPS growth (YoY) +8.3%
Net debt ₹72.7M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

RCAN reported revenue of ₹426M in FY2026 versus ₹251M in FY2022, a compound +14.1%/yr. Reported net income was ₹22.4M in FY2026, compounding +55.8%/yr from FY2022.

Revenue +14.1%/yr
FY22 ₹251M
FY23 ₹327M
FY24 ₹346M
FY25 ₹402M
FY26 ₹426M
Net income +55.8%/yr
FY22 ₹3.8M
FY23 ₹10.6M
FY24 ₹13.3M
FY25 ₹19.2M
FY26 ₹22.4M

Is RCAN fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "RCAN Fair Value". https://www.fairvalue-calculator.com/stock/RCAN

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is RCAN (RCAN) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹39.77 versus a price of ₹18.36 — about +117% (undervalued). Model-based estimate, not financial advice.
What is the fair value of RCAN?
Our model-based fair value for RCAN is ₹39.77 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹18.36.
What is the quality score of RCAN?
RCAN has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of RCAN (RCAN)?
RCAN reported trailing-twelve-month revenue of about ₹426M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of RCAN?
The net profit margin of RCAN is about 5.3%, meaning it keeps roughly 5.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.